TRYNGOLZA demonstrated significant fasting triglyceride level reductions compared with placebo at Month 61
The Balance trial was a randomized, placebo-controlled, double-blind clinical trial of 45 adults with FCS. The primary endpoint was mean percent change in fasting triglycerides from baseline to Month 6* compared with placebo.1
*Average of Weeks 23, 25, and 27.1
†Baseline mean fasting triglyceride levels were 2604 mg/dL.1
Primary endpoint
-42.5%
significant mean change in fasting triglycerides compared with placebo at Month 6
(95% CI, -74.1 to -10.9; P=0.0084)1†
*Average of Weeks 23, 25, and 27.1
†Baseline mean fasting triglyceride levels were 2604 mg/dL.1
The Ionis Every Step™ team are experts in rare disease who have been trained on familial chylomicronemia syndrome (FCS). We understand FCS, and that is why we offer patients prescribed TRYNGOLZA:
Personalized support from a dedicated Patient Education Manager*
Help navigating the insurance process†
Financial support offerings‡
Nutritional tools and resources
*Patient Education Managers do not provide clinical recommendations and will refer patients back to their HCP as necessary.
†Insurance approval is not guaranteed. Ionis Every Step offers financial assistance programs for patients who are uninsured or denied coverage for their Ionis medication.
‡Subject to program terms, conditions, and limits.
For more information about Ionis Every Step, call 1-844-789-8744 (Monday to Friday, 8 AM to 8 PM ET)
